Glimepiride (Amaryl®) in the Treatment of Patients with Diabetes Mellitus Type 2 (Pathophysiological Rationale and Clinical Implementation)

V.V. Poltorak, N.A. Kravchun, M.Yu. Gorshunskaya, N.S. Krasova

Abstract


The article provides an overview of data on the clinical efficacy of glimepiride (Amaryl®) in diabetes mellitus type 2: there are described the effect of glimepiride on insulin resistance, body weight, its antiatherogenic and antithrombotic effects, also an emphasis has been made on the safety of the drug.


Keywords


diabetes mellitus; glimepiride; insulin resistance; safety

References


Briscoe V.J. The role of glimepiride in the treatment of type 2 diabetes mellitus [Text] / V.J. Briscoe, M.L. Griffith, S.N. Davis // Expert Opin. Drug Metab. Toxicol. — 2010. — Vol. 6. — P. 225-235.

Insulin resistance differentially affects the PI 3-kinase and map kinase-mediated signaling in human muscle [Text] / K. Cusi, K. Maezono, A. Osman [et al.] // J. Clin. Invest. — 2000. — Vol. 105. — P. 311-320.

DeFronzo R.A. Insulin resistance, lipotoxity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 [Text] / R.A. DeFronzo // Diabetologia. — 2010. — Vol. 53. — P. 1270-1287.

Marquezine C.F. Molecular activity of insulin and selective insulin resistance [Text] / C.F. Marquezine, B.J. Wajchenberg // The Endocrinologist. — 2007. — Vol. 17. — P. 351-356.

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [Text] / D.M. Nathan, J.B. Buse, M.B. Davidson [et al.] // Diabetes Care. — 2009. — Vol. 32. — P. 193-203.

Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [Text] / S.E. Inzucchi, R.M. Bergenstal, J.B. Buse [et al.] // Diabetes Care. — 2012. — Vol. 35. — P. 1-16.

Wang L. Molecular mechanisms of insulin resistance that impact cardiovascular biology [Text] / L. Wang, M.L. Goalstone, B. Draznin // Diabetes. — 2004. — Vol. 53. — P. 2735-2740.

Draznin B. Molecular mechanisms of insulin resistance: serine phosporylation of insulin receptor substrate-1 and increased expression of p85alfa: the two sides of a coin [Text] / B. Draznin // Diabetes. — 2006. — Vol. 55. — P. 2392-2397.

Purnell J.Q. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity [Text] / J.Q. Purnell, C. Weyer // Treat Endocrinol. — 2003. — Vol. 2. — P. 33-47.

Muller G. Extrapancreatic effects of sulfonylureas — a comparison between glimeperide and conventional sulfonylureas [Text] / G. Muller, Y. Satoh, K. Geisen // Diabetes Res. Clin. Pract. — 1995. — Vol. 28. — P. 115-137.

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (amaryl): a double-blind comparison with glibenclamide [Text] / K.E. Draeger, K. Wernicke-Panten, H.J. Lomp [et al.] // Horm. Metab. Res. — 1996. — Vol. 28, № 9. — P. 419-425.

Полторак В.В. Амарил — сульфаниламидный препарат третьей генерации: роль в лечении сахарного диабета 2-го типа [Текст] / В.В. Полторак, Н.И. Горбенко // Український терапевтичний журнал. — 2001. — Т. 3, № 2. — С. 27-32.

Полторак В.В. Сахарный диабет 2-го типа: два патогенетических дефекта, две мишени для терапевтического воздействия [Текст] / В.В. Полторак, М.Ю. Горшунская // Ліки України. — 2010. — № 6(142). — С. 82-85.

Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes [Text] / M. Korytkowski, A. Thomas, L. Reid [et al.] // Diabetes Care. — 2002. — Vol. 25. — Р. 1607-1611.

Muller G. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics [Text] / G. Muller // Biochim. Biophys. Acta. — 1994. — Vol. 1191. — P. 267-277.

Differential interaction of glimepiride and glibenclamide with the b-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H] glimepiride [Text] / G. Muller, D. Hartz, J. Punter [et al.] // Biochim. Biophys. Acta. — 1994. — Vol. 1191. — P. 267-277.

Goldberg R.B. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol № 201 Study Group [Text] / R.B. Goldberg, S.M. Holvey, J. Schneider // Diabetes Care. — 1996. — Vol. 19. — P. 849-856.

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group [Text] / J. Rosenstock, E. Samols, D.B. Muchmore [et al.] // Diabetes Care. — 1996. — Vol. 19. — P. 1194-1199.

Schade D.S. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful [Text] / D.S. Schade, L. Jovanovic, J. Schneider // J. Clin. Pharmacol. — 1998. — Vol. 38. — P. 636-641.

Сучасна пероральна антидіабетична терапія [Текст]: Метод. рекомендації / Міністерство охорони здоров’я України, Національна академія медичних наук України / Н.О. Кравчун, Ю.І. Караченцев, В.В. Полторак, М.Ю. Горшунська, О.В. Козаков, Т.П. Левченко. — Х., 2007. — 20 с.

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients [Text] / G. Charpentier, F. Fleury, M. Kabir et al. // Diabet. Med. — 2001. — Vol. 18. — P. 828-834.

Применение амарила в комплексной терапии сахарного диабета типа 2 с метаболическим синдромом [Текст]: Метод. рекомендации / Министерство здравоохранения Украины, Академия медицинских наук Украины, Украинский центр научной медицинской информации и патентно-лицензионной работы / Н.А. Кравчун, Т.П. Левченко, В.В. Полторак, О.В. Козаков. — Х., 2004. — 20 с.

Garber A.J. Benefits of combination therapy of insulin and oral hypoglycemic agents [Text] / A.J. Garber // Arch. Intern. Med. — 2003. — Vol. 163. — P. 1781-1782.

Riddle M.C. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine [Text] / M.C. Riddle // Horm. Metab. Res. — 1996. — Vol. 28. — P. 430-433.

Kabadi M.U. Efficacy of sulfonylureas with insulin in type 2 diabetes meilitus [Text] / M.U. Kabadi, U.M. Kabadi // Ann. Pharmacother. — 2003. — Vol. 37. — P. 1572-1576.

Monnier L. The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts? [Text] / L. Monnier, C. Colette, D. Owens // Diabetes Res. Clin. Pract. — 2012. — Vol. 95. — P. 303-311.

Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus [Text] / M. Muggeo, G. Verlato, E. Bonora [et al.] // Circulation. — 1997. — Vol. 96. — P. 1750-1754.

Fritsche A. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial [Text] / A. Fritsche, M.A. Schweitzer, H.U. Haling // Ann. Intern. Med. — 2003. — Vol. 38. — P. 952-959.

Muller G. The molecular mechanism of the insulin-mimetic/ sensitizing activity of the antidiabetic sulfonylurea drug amaryl [Text] / G. Muller // Mol. Med. — 2000. — Vol. 6. — P. 907-933.

Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes [Text] / D. Overkamp, A. Volk, E. Maerker et al. // Diabetes Care. — 2002. — Vol. 25. — P. 2065-2073.

Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis [Text] / K. Koshiba, M. Nomuro, Y. Nakaya [et al.] // Journ. Med. Invest. — 2006. — Vol. 53. — P. 87-94.

Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects [Text] / T. Tsunekawa, T. Hayashi, Y. Suzuki [et al.] // Diabetes Care. — 2003. — Vol. 26. — P. 285-289.

Efficacy of glimepiride in Japanese type 2 diabetic subjects [Text] / K. Inukai, M. Watanabe, Y. Nakashima [et al.] // Diabetes Res. Clin. Pract. — 2005. — Vol. 68. — P. 250-257.

Sulfonylurea stimulates liver fructose-2, 6-biphospate formation in proportion to its hypoglycemic action [Text] / K. Hatao, K. Kaku, M. Matsuda [et al.] // Diabetes Res. Clin. Pract. — 1985. — Vol. 1. — P. 49-53.

Effect of glimepiride (HOE 490) on insulin receptors of sceletal muscles from genetically diabetic KK-Ay mouse [Text] / Y. Takada, Y. Takata, M. Iwanishi [et al.] // Eur. J. Pharmacol. — 1996. — Vol. 308. — P. 205-210.

Muller G. Characterization of the molecular mode of action of the sulfonylurea, glimeperide, at adipocytes [Text] / G. Muller, K. Geisen // Horm. Metab. Res. — 1996. — Vol. 28. — P. 469-487.

Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide [Text] / A. Haupt, C. Kausch, D. Dahl [et al.] // Diabetes Care. — 2002. — Vol. 25. — P. 2129-2132.

Campbell R.K. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus [Text] / R.K. Campbell // Ann. Pharmacother. — 1998. — Vol. 32. — P. 1044-1052.

Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the anti-diabetic sulfonylurea drug, glimepiride, in rat adipocytes [Text] / G. Muller, S. Wied, J. Straub [et al.] // Eur. J. Pharmacol. — 2008. — Vol. 597. — P. 6-18.

Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin [Text] / R.C.T. Mori, S.M. Hirabara, A.E. Hirata [et al.] // Diabetes, Obesity and Metabolism. — 2008. — Vol. 1111. — P. 1463-1326.

Glimepiride reduces mononuclear activation of the redoxsensitive transcription nuclear factor-kappaB [Text] / S. Schiekofer, G. Rudofsky Jr, M. Andrassy [et al.] // Diabetes Obes. Metab. — 2003. — Vol. 5. — P. 251-261.

NF-κB, MEF-2A, MEF-2D and HIF1a involvement on insulin and contraction-induced regulation of GLUT4 gene expression in soleus muscle [Text] / J.L.T. Silva, G. Giannocco, D.T. Furuya [et al.] // Moll. Cell. Endocrynol. — 2005. — Vol. 240. — P. 82-93.

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase [Text] / T. Yamauchi, J. Kamon, Y. Monokoshi [et al.] // Nat. Med. — 2002. — Vol. 8. — P. 1288-1295.

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1 [Text] / O.N. Ozes, H. Akca, L.D. Mayo [et al.] // Proc. Natl. Acad. Sci. — 2001. — Vol. 98. — P. 4660-4645.

Tumour necrosis factor-alpha regulates expression of CCAAT-enhancer-binding proteins (C/EBPs) alpha and beta and determines the occupation of the C/EBP site in the promoter of the insulin-responsive glucose-transporter gene in 3T3-L1 adipocytes [Text] / R. Jain, S. Police, K. Phelps [et al.] // Biochem. J. — 1999. — Vol. 338. — P. 737-743.

Novel modulator for endothelial adhesion molecules: adipocyte-derived receptor gamma agonistic activity [Text] / N. Ouchi, S. Kihara, Y. Arita [et al.] // Biochem. J. — 1999. — Vol. 100. — P. 2473-2476.

Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity [Text] / Y. Mori, H. Komiya, N. Kurokawa [et al.] // Diabetes Obes. Metab. — 2004. — Vol. 6. — P. 28-34.

Sulfonylurea agents exhibit peroxisome proliferatorsactivated receptor gamma agonistic activity [Text] / S. Fukuen, M. Iwaki, A. Yasui [et al.] // J. Biol. Chem. — 2005. — Vol. 280. — P. 23653-23659.

Glimepiride enhances intrinsic peroxisome proliferatoractivated receptor-gamma activity in 3T3-L1 adipocytes [Text] / K. Inukai, M. Watanabe, Y. Nakashima [et al.] // Biochem. Byophys. Res. Commun. — 2005b. — Vol. 328. — P. 484-490.

Sun Y. Effects of Amaryl on Aquaporin-1 expression in diabetic rats [Electronic resourse] / Y. Sun, H. Wang // 72nd Scientific sessions of American Diabetes Assoaciation, 8-12 June 2012, Philadelphia, USA. — Abstract 470-P. — 1 електрон. опт. диск (CD-ROM).

Davis S.N. The role of glimepiride in the effective management of type 2 diabetes [Text] / S.N. Davis // J. Diabetes Complications. — 2004. — Vol. 18. — P. 367-376.

Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis [Text] / C. Bugos, M. Austin, T. Atherton [et al.] // Diabetes Res. Clin. Pract. — 2000. — Vol. 50, Suppl. 1. — S. 47.

Efficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort study [Text] / G. Scholz, K. Schneider, W. Knirsch [et al.] // Diabetes Res. Clin. Pract. — 2001. — Vol. 21. — P. 597-604.

Change in patients’ body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort study [Text] / S. Martin, H. Kolb, J. Beuth [et al.] // Diabetologia. — 2003. — Vol. 46. — P. 1611-1617.

Umpierrez G. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial [Text] / G. Umpierrez, M. Issa, A. Vlajnic // Curr. Med. Res. Opin. — 2006. — Vol. 22. — P. 751-759.

Effects of glimepiride on HbA(1c) and body weight in type 2 diabetes: results of a 1.5-year follow-up study [Text] / R. Weitgasser, M. Lechleitner, A. Luger [et al.] // Diabetes Res. Clin. Pract. — 2003. — Vol. 61. — P. 13-19.

Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMPdependent pathway [Text] / N. Ouchi, S. Kihara, Y. Arita [et al.] // Circulation. — 2000. — Vol. 102. — P. 1296-1301.

Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages [Text] / N. Yokota, K. Oritani, I. Takahashi [et al.] // Blood. — 2000. — Vol. 96. — P. 1723-1732.

Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages [Text] / N. Ouchi, S. Kihara, Y. Arita [et al.] // Circulation. — 2001. — Vol. 103. — P. 1057-1063.

Metabolic variations with oral antidiabetic drugs in patients with type 2 diabetes: comparison between glimepiride and metformin [Text] / G. Deroza, I. Franzetti, G. Gadaleta [et al.] // Diabetes Nutr. Metab. — 2004. — Vol. 17. — P. 143-150.

Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Act dependent pathway [Text] / H. Ueba, M. Kuroki, S. Hashimoto [et al.] // Atherosclerosis. — 2005. — Vol. 183. — P. 35-39.

The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus [Text] / B. Yang, H. Tian, Y. Ren [et al.] // Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 22 (English Abstract). — 2005. — P. 560-564.

Treatment of endothelial dysfunction with glimepiride + metformin in patients with type 2 diabetes mellitus: evaluation with position emission tomography [Text] / E. Alexanderson, G. Alexanderson, C. Sierra [et al.] // Diabetologia (Abstracts of the 43rd EASD Annual Meeting, Netherlands). — 2007. — Vol. 50. — Abstract. 1177. — S. 483.

Centers for Disease Control and Prevention; American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association [Text] / T.A. Pearson, G.A. Mensah, R.W. Alexanderson [et al.] // Circulation. — 2003. — Vol. 107. — P. 499-511.

Glimeperide enhaces intrinsic peroxisome proliferatoractivated receptor-gamma activity in 3T3-L1 adipocytes [Text] / K. Yunukai, M. Watanabe, Y. Nakashima [et al.] // Biochem. Byophys. Res. Commun. — 2005. — Vol. 328. — P. 484-490.

Adiponectin is associated with vascular function independent of insulin sensitivity [Text] / J.M. Fernandez-Real, A. Castro, G. Vasques [et al.] // Diabetes Care. — 2004. — Vol. 27, № 3. — P. 739-745.

Шустов С.Б. Влияние Амарила® на углеводный, липидный обмен и гемодинамику у больных сахарным диабетом 2-го типа [Текст] / С.Б. Шустов, Б.В. Ромашевский, А.Г. Лысенко // Сахарный диабет. — 2001. — № 4. — С. 42-45.

Antiagregattory activity of hypoglycaemic sulphonylureas [Text] / D. Siluk, R. Kaliszan, P. Haber [et al.] // Diabetologia. — 2002. — Vol. 45. — P. 1034-1037.

Prophylactic effect of the sulphonylurea, glimepiride, on atherosclerosis [Text] / S. Shakuto, Y. Sato, K. Oshima [et al.] // Diabetologia (Abstracts of the 38th Annual Meeting of the EASD, Hungary). — 2002. — Vol. 45, suppl. 2. — Abstract 853. — P. A275.

Effects of glimepiride and gliclazide on cardiac arrhytmias in patients with type 2 diabetes and cardiac insufficiency [Text] / Pogatsa G. [et al.] // Diabetes. — 2001. — Vol. 50, Suppl. 1: A128. — Abstract 513P.

Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus [Text] / D.-Y. Xu, S.-P. Zhao, Q.-X. Huang [et al.] // Diabetes Res. Clin. Pract. — 2010. — Vol. 88. — P. 71-75.

Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients [Text] / D. Nagayama, A. Saiki, K. Endo [et al.] // Int. J. Clin. Pract. — 2010. — Vol. 64, № 13. — P. 1796-1801.

SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together [Text] / F. Paneni, M. Volpe, T.F. Luscher, F. Cosentino // Diabetes. — 2013. — Vol. 62. — P. 1800-1807.

Sanofi-Aventis Canada, Inc. Product Monograph (Amaryl, glimepiride). — 2009.

Holstein A. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide [Text] / A. Holstein, A. Plaschke, E.H. Egberts [et al.] // Diabetes Metab. Res. Rev. — 2001. — Vol. 17. — P. 467-473.

The effects of acute exercise on metabolic control in type 2 diabetic patients treated with glimepiride or glibenclamide [Text] / M. Massi-Benedetti, M. Herz, C. Pfeiffer [et al.] // Horm. Metab. Res. — 1996. — Vol. 28. — P. 451-455.

Scientific monograph Amaryl® 3rd revised edition [Text] / A. Diedenhofen, B. Rosenkranz, R. Robkamp [et al.] // Aventis Pharma. — 2000. — P. 1-114.

Muller G. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro [Text] / G. Muller, S. Wied // Diabetes. — 1993. — Vol. 42. — P. 1852-1867.

Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus [Text] / R.A. Whitmer, A.J. Karter, K. Yaffe [et al.] // JAMA. — 2009. — Vol. 301. — P. 1565-1572.

Sulfonylureas and ischemic preconditioning; a double-blind, placebo-controlled evaluation of glimeperide and glibenclamide [Text] / H. Klepzing, G. Kober, C. Matter [et al.] // Eur. Heart J. — 1999. — Vol. 20. — P. 439-446.

Александров А.А. Сахароснижающая терапия и сердце: бремя доказательств [Текст] / А.А. Александров // Consilium Medicum. — 2002. — Т. 4, № 10. — С. 551-554.

Caulfield M. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues [Text] / M. Caulfield, K. O’Brien [et al.] // Clin. Diabetes. — 2002. — Vol. 20. — P. 81-84.

Lee T.M. Impairment of myocardial protection in type 2 diabetic patients [Text] / T.M. Lee, T.F. Chou // J. Clin. Endocrinol. Metab. — 2003. — Vol. 88. — P. 531-537.

Полторак В.В. Блокада К-АТФ-каналів препаратами сульфонілсечовини та кардіоваскулярна безпека у хворих на цукровий діабет 2 типу [Текст] / В.В. Полторак, Н.І. Горбенко, М.Ю. Горшунська // Український медичний часопис. — 2002. — № 6(32). — С. 65-78.

Murry C.E. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium [Text] / C.E. Murry, R.B. Jenning, K.A. Reimer // Circulation. — 1986. — Vol. 74, № 5. — P. 1124-1136.

Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide [Text] / M.M. Mocanu, H.L. Мaddock, G.F. Baxter [et al.] // Circulation. — 2001. — Vol. 103, № 25. — P. 3111-3116.

Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemoc preconditioning in rabbits [Text] / Е. Nieszner, I. Posa, E. Kocsis [et al.] // Exp. Clin. Endocrinol. Diabetes. — 2002. — Vol. 110. — P. 212-218.

The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium [Text] / U. Quast, D. Stephan, S. Bieger, U. Russ // Diabetes. — 2004. — Vol. 53, Suppl. 3. — P. S156-164.

Ferdinandi P. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning [Text] / P. Ferdinandi, R. Schulz, G.F. Baxter // Pharmacol. Rev. — 2007. — Vol. 59. — P. 418-458.

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction [Text] / К. N. Garratt, P.A. Brady, N.L. Hassinger [et al.] // J. Am. Coll. Cardiol. — 1999. — Vol. 33. — P. 119-124.

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin [Text] / J.M. Evans, S.A. Ogston, A. Emslie-Smith, A.D. Morris // Diabetologia. — 2006. — Vol. 49. — P. 930-936.

Csont T. Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance [Text] / T. Csont, P. Ferdinandy // Pharmacol. Ther. — 2005. — Vol. 105, № 1. — P. 57-68.

Ferdinandi P. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning [Text] / P. Ferdinandi, R. Schulz, G.F. Baxter [et al.] // Pharmacol. Rev. — 2007. — Vol. 59. — P. 418-458.

Contribution of both sarcolemmal K-ATP and mitochondrial K-ATP channels to infarct size limitation by K-ATP channels openers: differences from preconditioning in the role of sarcolemmal K-ATP channels [Text] / M. Tanno, T. Miura, A. Tsuchida [et al.] // Naunyn-Schmiedeberg’s Arch. Pharmacol. — 2001. — Vol. 364. — P. 226-232.

All-cause mortality in diabetic patients treated with combination of sulfonylureas and biguanides [Text] / E. Mannucci, M. Monami, G. Masotti [et al.] // Diabetes Metab. Res. Rev. — 2004. — Vol. 20. — P. 44-47.

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis [Text] / K.M. Pantalone, M.W. Kattan, C. Yu [et al.] // Diab. Obes. Metab. — 2012. — Vol. 14. — P. 803-809.

Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus [Text] / Ch-H. Chang, J-W. Lin, L-Ch. Wu [et al.] // J. Clin. Endocrinol. Metab. — 2012. — Vol. 97. — P. E1-E6.

Kabadi, U.M. Cost-effective management of hyperglycemia in patient with type 2 diabetes using oral agents [Text] / U.M. Kabadi // Managed Care. — 2004. — Vol. 6. — Р. 48-59.

Antidiabetic therapy in renal practice: indicators for adherence and treatment cost [Text] / G.L. Colombo, E. Rossi, M. De Rosa [et al.] // Patient Pref. Adher. — 2012. — Vol. 6. — P. 653-661.

Meredith P. Bioequivalence and other unresolved issues in generic drug substitution [Text] / P. Meredith // Clinical Therapeutic. — 2003. — Vol. 25, № 11. — P. 2875-2890.

Рудык Ю.С. Терапевтическая эквивалентность лекарственных средств и возможные источники ошибок [Текст] / Ю.С. Рудык // Здоров’я України. — 2007. — № 12(1). — С. 71-73.

Полторак В.В. Критерии замены оригинальных лекарственных средств генериками [Текст] / В.В. Полторак, В.В. Липсон, Л.Е. Никишина // Проблеми ендокринної патології. — 2008. — № 3. — С. 83-96.

Brand and generic medications: are they interchangeable? [Text] / A.S. Al-Jazairi, S. Bihareth, I.S. Eqtefan [et al.] // Ann. Saudi Med. — 2008. — Vol. 28, № 1. — P. 33-41.

Bioequivalence assessment of the two brands of glimeperide tablets [Text] / D. Jovanovic, D. Stojsic, M. Zlatkovic [et al.] // Vojnosanit Pregl. — 2006. — Vol. 63, № 12. — P. 1015-1020.

Attorrese G. Quality and behavior of glimeperide generics versus amaryl under stressed conditions [Text] / G. Attorrese, M. Massi-Benedetti // Diabetes Technology & Therapeutics. — 2007. — Vol. 9, № 3. — P. 287-296.




DOI: https://doi.org/10.22141/2224-0721.1.57.2014.76425

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru